Selected Publications

Manuscripts

 

A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome.

Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L, Shrewsbury SB. J Urol. 2016;196(3):747-754.


The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma.

Leaker BR, Barnes PJ, O'Connor BJ, et al. Clin Exp Allergy. 2014;44(9):1146-1153.

 

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo

Stenton GR, Mackenzie LF, Tam P, et al.  Br J Pharmacol. 2013;168(6):1506-1518.

 

Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.

Stenton GR, Mackenzie LF, Tam P, et al. Br J Pharmacol. 2013;168(6):1519-1529. 

 

Aquinox Scientific Presentations

IC/BPS

111th American Urological Association (AUA) Annual Meeting – San Diego, CA; May 6-10, 2016

SHIP-1 Activation Provides Significant Benefit in Interstitial Cystitis/Bladder Pain Syndrome: Results of a Phase 2 Randomized Placebo Controlled Trial 

Nickel JC, Egerdie B, Davis E, Evans R, Biagi H, Shrewsbury S 

Click here to view poster.

 

Plasma and Urinary Pharmacokinetics of a Novel, Oral SHIP1 Activator AQX-1125 in Female Patients with Interstitial Cystitis

Nickel JC, Evans R, Tam P, Toews J, Mackenzie LF, Biagi H, Shrewsbury S 

Click here to view poster.

 

Effect of AQX-1125 on Urinary Bladder Inflammation and Pain Induced by Cyclophosphamide in Rats, by Targeting the SHIP1 Pathway

Cross JL, Harwig C, Tam P, Toews J, Mackenzie LF 

Click here to view poster.

 

31st European Association of Urology (EAU) Annual Congress – Munich, Germany; March 11-15, 2016

Plasma and Urinary Pharmacokinetics of the Novel, Oral SHIP1 Activator, AQX-1125 in Interstitial Cystitis/ Bladder Pain Syndrome (IC/BPS) –Results of the Phase 2 LEADERSHIP Trial

Nickel JC, Evans R, Tam P, Toews J, Mackenzie LF, Biagi H, Shrewsbury S

Click here to view poster.

 

Hematology

58th Annual American Society of Hematology (ASH) Meeting – San Diego, CA; December 3-6, 2016

Chemical Activation of the SHIP1 Inositol Lipid Phosphatase: A Novel Therapeutic Strategy to Suppress B-Cell Receptor Signaling and CXCR4 Expression in Malignant Human B Cells

Packham G, Valle-Argos B, Lemm E, Smith LD, Weston-Bell NJ, Gebreselassie Y, Steele AJ, Stevenson FK, Cragg MS, Forconi F, Cross J, Harwig C, Mackenzie L

Click here to view poster.

 

Hepatic Disease

Keystone Symposia’s 2015 conference on: Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) - Whistler, BC; March 22-27, 2015

AQX-1125, a Small Molecule SHIP1 Activator, is Effective in a Murine NASH Model

Cross JL, Harwig D, Tam P, Toews J, Mackenzie LF

Click here to view poster.

 

Pulmonary Disease

American Thoracic Society (ATS) 2014 - San Diego, CA; May 16-21, 2014

The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway

Bjermer L, Vestbo J, Kuna P, Saarelainen P, Balint. B, Kalia V, Tam P, Mackenzie L, Shrewsbury S

Click here to view poster.

 

American Thoracic Society 2013 - Philadelphia, PA; May 17-22, 2013

The Effects Of AQX-1125, A Selective Oral SHIP1 Activator, On Lipopolysaccharide-Induced Cellular and Biochemical Changes in Sputum From Healthy Volunteers

Elborn JS, Smith SP, Brown V, Chernoff D, Tam P, Neville J, Toews J, Stenton GR, Harwig C, MacRury T, Mackenzie LF

Click here to view poster.

 

The Effects Of The Novel SHIP1 Activator AQX-1125 On Allergen-Induced Responses In Mild To Moderate Asthma

Leaker BR, O’Connor BJ, Barnes PJ, Chernoff D, Tam P, Neville J, Toews J, Stenton GR, Harwig C, MacRury T, Mackenzie LF

Click here to view poster.

 

Prophylactic or therapeutic AQX-1125, a small molecule SHIP1 activator, inhibits bleomycin-induced pulmonary fibrosis in mice

Stenton GR, Mackenzie LF, Esposito E, Cuzzocrea S, Szabo C, MacRury T 

Click here to view poster.